What does AVRA do?
Bringing researchers together
AVRA will deploy advanced technologies, including those used to develop Australia’s leading COVID-19 vaccine candidate, to develop vaccines against emerging viral pathogens and antibiotic resistant superbugs that cause human disease, and to build long-term sovereign capability to rapidly respond to future infectious disease threats.
The alliance brings together leading research and development organisations in Australia and world-class researchers to rapidly develop, manufacture and deliver effective vaccines in response to national and global infectious disease threats. AVRA will establish a new level of sustained coordination and collective effort for vaccine development, integrating Australia’s infectious disease research activity and expertise into a translational vaccine pipeline with industry to address the two-fold threat of emerging viral pathogens with pandemic potential, and antibiotic resistant superbugs.
The pipeline will deliver the essential activities for effective vaccine development, including (1) antigen surveillance, encompassing both enabling and investigative research, (2) application of existing and novel vaccine technologies and platforms to generate vaccine candidates, and (3) advanced biomanufacturing and clinical trials. AVRA will build the workforce and infrastructure capabilities that are integral to preparedness and that will allow a decisive response to new infectious disease threats.
Through strategic collaborations and supply chain partnerships with small and medium enterprises (SMEs), government agencies and global pharmaceutical companies, AVRA will ensure that Australia has the capacity, structures and systems needed to respond rapidly and effectively to current (e.g. antibiotic resistant superbugs, COVID-19) and future global infectious disease emergencies.
The alliance brings together leading research and development organisations in Australia and world-class researchers to rapidly develop, manufacture and deliver effective vaccines in response to national and global infectious disease threats. AVRA will establish a new level of sustained coordination and collective effort for vaccine development, integrating Australia’s infectious disease research activity and expertise into a translational vaccine pipeline with industry to address the two-fold threat of emerging viral pathogens with pandemic potential, and antibiotic resistant superbugs.
The pipeline will deliver the essential activities for effective vaccine development, including (1) antigen surveillance, encompassing both enabling and investigative research, (2) application of existing and novel vaccine technologies and platforms to generate vaccine candidates, and (3) advanced biomanufacturing and clinical trials. AVRA will build the workforce and infrastructure capabilities that are integral to preparedness and that will allow a decisive response to new infectious disease threats.
Through strategic collaborations and supply chain partnerships with small and medium enterprises (SMEs), government agencies and global pharmaceutical companies, AVRA will ensure that Australia has the capacity, structures and systems needed to respond rapidly and effectively to current (e.g. antibiotic resistant superbugs, COVID-19) and future global infectious disease emergencies.